Cell therapy continues to transform the oncology field with advances across in vivo engineering and novel armouring enhancements, but this year has also seen the translation of cell therapies’ curative potential into the autoimmune space to capitalise on their targeting abilities. Despite investment challenges, innovation not slowing for those working in CAR-T and TCR drug development, as the mission to engineer a disease-free world remains front of mind.  

Providing your team with exclusive access to the most cutting-edge advances across pre-clinical platforms, clinical advances, and streamlined manufacturing, the 7^th CAR-TCR Summit Europe is your must-attend forum to stay at the forefront of cell therapy innovations.  

300+ industry experts will unite in London this February 27-29 to brainstorm everything from boosting clinical durability, advancing predictive biomarkers, and implementing safety switches through to automating production and accelerating analytical processes to reduce operational costs and turnaround times.  

With leading next-gen stakeholders like ImmPACT Bio, Immatics, Caribou Bio, Umoja Biopharma, Mnemo Therapeutics, and ArsenalBio alongside key investors already confirmed to be in attendance, can your team afford to miss out?